Skip to main navigation Skip to search Skip to main content

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study: 5 Independent Sub-studies of Setmelanotide in Patients with POMC, PCSK1, LEPR, SRC1, SH2B1, and PCSK1 N221D Gene Defects in the Melanocortin-4 Receptor Pathway

Project: Research

Project Details

StatusActive
Effective start/end date07/14/22 → 12/31/26

Funding

  • Rhythm Pharmaceuticals Incorporated: $92,377.47